Dr. Hathaway completed training in the Bredesen protocol and is working closely with Dr. Bredesen and other physicians to advance the understanding and application of this program to reverse cognitive decline.
Here is a link to Dr Bredesen’s information site for patients, their families and physicians:
The global burden of dementia is staggering, and unfortunately on the rise. Of the 318 million Americans currently living, 45 million will develop Alzheimer’s disease. There are 75 million Americans with ApoE4, the most important genetic risk factor for Alzheimer’s disease. It is expected that by 2050, there will be over 160,000,000 patients with Alzheimer’s disease globally. For women, Alzheimer’s is more common than breast cancer, as women make up over 65% of the patients and 60% of the caregivers. How can we improve this dire situation?
Dr. Dale Bredesen has spent over 30 years researching the treatment and prevention of Alzheimer’s disease, and has recently published the first paper on the Reversal Of Cognitive Decline in patients with early Alzheimer’s disease and its precursors. This is a summary of the publication:
This report describes a novel, comprehensive, and personalized therapeutic program that is based on the underlying pathogenesis of Alzheimer’s disease, and which involves multiple modalities designed to achieve metabolic enhancement for neurodegeneration (MEND). The first 10 patients who have utilized this program include patients with memory loss associated with Alzheimer’s disease (AD), amnestic mild cognitive impairment (aMCI), or subjective cognitive impairment (SCI). Nine of the 10 displayed subjective or objective improvement in cognition beginning within 3-6 months, with the one failure being a patient with very late stage AD. Six of the patients had had to discontinue working or were struggling with their jobs at the time of presentation, and all were able to return to work or continue working with improved performance. Improvements have been sustained, and at this time the longest patient follow-up is two and one-half years from initial treatment, with sustained and marked improvement. These results suggest that a larger, more extensive trial of this therapeutic program is warranted. The results also suggest that, at least early in the course, cognitive decline may be driven in large part by metabolic processes. Furthermore, given the failure of monotherapeutics in AD to date, the results raise the possibility that such a therapeutic system may be useful as a platform on which drugs that would fail as monotherapeutics may succeed as key components of a therapeutic system.
To see the full study go to: